Biomodels prides itself on the unique approach we take toward our client relationships. Working primarily with biotechnology and pharmaceutical companies, our services go far beyond what you might expect from a traditional contract research organization (CRO). Most CROs offer standardized assays, but the inflexibility of this approach is not well suited for the design and completion of studies to elucidate efficacy and mechanism of action. At Biomodels, we take a significantly broader view of the drug development process and deliver personalized services conceived as part of a truly collaborative client relationship.

The ultimate goal of our firm is to help our clients rapidly accomplish their scientific objectives and thus save valuable time and resources. For typical clients, this means acquiring supporting preclinical data to justify further studies of their lead compound or biologic in human clinical trials. Most frequently, the desired objective is the filing of an IND application. However, we can also assist in the evaluation of new (or halo) indications, assessment of new technologies, and due diligence pertaining to licensing, venture capital financing, and/or mergers and acquisitions.

We recognize that outsourcing of key tasks is the primary driver in the ability of established and start-up life science companies to achieve their scientific goals within budget and meet, in a timely manner, the milestones set by equity stakeholders. Understandably, younger (or smaller) companies in particular feel uneasy with this level of outside time and resource commitment at such a critical juncture in their lifecycle. Biomodels can help alleviate these fears. Our most valuable assets are unparalleled clinical expertise and documented success helping similar companies successfully clear regulatory hurdles. These same attributes make Biomodels a cost-effective alternative and result in a decreased amount of time in the preclinical phase of drug development.